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Abstract
MicroRNAs are small RNA molecules that regulate gene expression and play critical roles in B cell development and
malignancy. miRNA expression is important globally, as B cell specific knockouts of Dicer show profound defects in
B cell development; and is also critical at the level of specific miRNAs. In this review, we discuss miRNAs that are
involved in normal B cell development in the bone marrow and during B cell activation and terminal
differentiation in the periphery. Next, we turn to miRNAs that are dysregulated during diseases of B cells, including
malignant diseases and autoimmunity. Further study of miRNAs and their targets will lead to a better
understanding of B cell development, and should also lead to the development of novel therapeutic strategies
against B cell diseases.
Introduction
In a relatively short time period, gene expression regula-
tion by microRNAs (miRNAs) has changed the way that
we view developmental and pathological processes.
From initial discoveries in C. elegans, the identification
of the novel small RNA biogenesis pathway and the
identification of RNA interference, the field has moved
rapidly [1-6]. The involvement of miRNAs in hemato-
poiesis has now been documented by numerous groups
and they seem to regulate almost every aspect of hema-
topoietic development. In this review we focus on B cell
development, where the importance of gene expression
regulation has been appreciated for many years. miR-
NAs have emerged as critical regulators of gene expres-
sion and regulate many aspects of B cell development,
and are dysregulated in B cell malignancies. Here, we
review many of the studies that have been performed to
delineate the roles of miRNAs in development and
malignant transformation of B cells.
MicroRNA biogenesis
miRNAs are non-protein coding RNAs of about 19-23
nucleotides. They are post-transcriptional gene regula-
tors that bind to partially complementary sequences in
the 3’ UTR on target messenger RNA transcripts,
thereby causing downregulation of the target [7]. They
were first discovered in 1993 in C. elegans by Victor
Ambros, during a study of lin-14. They identified a
small RNA product encoded by lin-4 gene that is
responsible for the downregulation of LIN-14 protein
[2,3,8]. This central dogma of miRNA action has proven
to stand the test of time, as miRNAs in most organisms
are thought to behave similarly.
miRNAs can be grouped in to at least three categories
depending on their genomic location: exonic miRNAs in
non-coding genes, intronic miRNAs in non-coding
genes and intronic miRNAs in protein-coding genes [9].
miRNAs are expressed as long primary RNA (pri-
miRNA) as part of RNA polymerase II-driven transcript
[10]. Therefore, it is possible that some miRNAs are co-
regulated with their host gene as a part of transcrip-
tional regulation during B cell development. The pri-
miRNA is recognized by RNA binding protein DGCR8
and is processed by RNase III-type protein Drosha in
the nucleus yielding a pre-mRNA [11,12]. Pre-miRNA is
then exported to the cytoplasm by Exportin-5 where it
is further processed by a second RNase III-type enzyme,
Dicer, to produce a mature miRNA duplex [13]. The
19-25 nucleotide-long double stranded miRNA duplex is
then unwound and incorporated into RNA-induced
silencing complex (RISC), with strand selection based
on thermodynamic properties. In the RISC, the miRNA
binds to the target sequence in the 3’ UTR via 6-8
nucleotide seed region and downregulates the expres-
sion of the target either by direct degradation or desta-
bilization and eventually degradation of the target
[14-16]. Since the repression is achieved by
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complementary base pairing via a relatively short seed
sequence, miRNAs are predicted to have multiple tar-
gets. A genome wide statistical analysis has shown that
one miRNA can have hundreds of targets, indicating
their critical role in post translation regulation [17]. It
should be noted that recently, a Dicer-independent
miRNA biogenesis pathway has also been reported. This
pathway utilizes the catalytic activity of Argonaute2
(Ago2) [18-21]. miR-451 is the best characterized
miRNA that is produced independently of Dicer and is
involved in erythropoiesis. The unusual short stem
structure of pre miR-451 promotes the binding and pro-
cessing by Ago2 [19].
miRNAs have already found to influence immune cell
differentiation. Recently, it was found that Dicer and
miRNA play vital roles in both early and late B cell dif-
ferentiation [22,23]. Deletions of individual miRNA
genes are associated with several immune defects. In
many instances, dysregulated expression of miRNAs has
been seen in malignancies in the immune system, which
we will discuss in detail later in the review.
B cell development
B cells are responsible for adaptive humoral immunity.
B cell development is characterized by complex
sequence of molecular events that is regulated by B -
lineage transcription factors. It is evident that miRNAs
play a major role in modulating the expression of these
transcription factors and thereby the normal
development of B cells. Conversely, dysregulation of
miRNA expression is thought to be a key factor to the
pathogenesis of B cell malignancies, including progenitor
B cell-malignancies such as B-lymphoblastic leukemia
(also referred to as B-Acute lymphoblastic leukemia or
B-ALL) and mature B cell malignancies including sev-
eral types of non-Hodgkin lymphoma. B cell develop-
ment begins in the fetal liver and continues in the bone
marrow of adult throughout the life (reviewed in
[24,25]). The process of B cell formation starts in the
bone marrow and ends in the peripheral secondary lym-
phoid organs such as the spleen (Figure 1). Here, we
provide a primer on B cell development to orient the
discussion on the role of miRNAs in B cells.
Bone marrow B cell development
In the bone marrow, cellular stages of development
include the common lymphoid progenitor, pro-B cell,
pre-B cell and immature-B cell stages. These stages of B
cells are defined by the expression and the re-arrange-
ment of functional B cell receptor (BCR)/immunoglobu-
lin (Ig) genes. Complex and elegant mechanisms have
evolved to generate a diverse repertoire of BCRs against
the vast variety of antigen that we encounter in our life-
time. This diversity is achieved by V (D)J recombination
of the immunoglobulin locus, which is a process of
somatic recombination that brings together various gene
segments within the heavy and light chain loci. The
heavy chain is assembled from Variable (V), Diversity
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Figure 1 miRNAs involved in B cell development in the bone marrow and periphery. B cells development starts in the bone marrow and
achieves a remarkable diversity of immunoglobulin loci by V(D)J recombination. Immature B cells migrate to the secondary lymphoid organs
where they are activated by specific antigens. Once they are activated, they undergo proliferation and further differentiation into plasma cells
that secrete antibodies or memory B cells that can be reactivated with a secondary infection. There are at least three different types of mature B
cells: B1 cells, conventional follicular B2 cells and marginal-zone B cells. miRNAs that are involved in different stages of B cell development are
indicated above the arrows. Secondary diversification of the immunoglobulin loci is achieved by SHM and CSR at the germinal center.
Abbreviations, CLP: Common lymphoid progenitor; MZB: marginal zone B cells; CB: Centroblasts; CC: Centrocytes; PC: Plasma Cell; Mem: Memory
cell; SHM: Somatic Hypermutation; CSR: Class switch recombination.
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(D) and Joining (J) gene exons that somatically recom-
bine with the Constant (C) region exons to generate
unique immunoglobulins of differing antigenic specifi-
city. On the other hand, the light chain variable region
is composed of only a V and J segments. The numbers
of these gene segments are highly variable in different
species and the different segments seem to have evolved
from gene duplications from ancestral V-gene exons.
Each V-, D-, and J- gene segment is flanked by DNA
sequence called recombination signaling sequence,
which is recognized by RAG1 and RAG2 enzymes,
which mediate recombination. Random selection of
these segments during V(D)J recombination and junc-
tional diversity introduced by addition or subtractions of
nucleotides at the junctions of these segments enable
the production of vast variety of Ig (reviewed in
[26-32]).
The stages of B cell development have been defined by
the steps in V(D)J recombination. The Pro-B cell stage
is characterized by rearrangement of Ig heavy chain,
which occurs first. D-J joining occurs first, following
which the DJ segment is joined to a V segment. D-J
rearrangement starts in the common lymphoid progeni-
tor and occurs mainly in early pro-B cells. V-DJ rearran-
gement occurs in late pro-B cells. The assembled heavy
chain is then expressed on the surface of the pre-B cells
along with a surrogate light chain. The pro-B cell to
pre-B cell transition is accompanied by cell proliferation.
Rearrangement of the light chain by V to J joining
occurs during the pre-B cell stage. Successful assembly
of light chain leads to the expression of complete IgM
molecule at the surface and if the rearrangement is suc-
cessful, signal transduction from IgM binding allows for
differentiation into an immature B cell. Immature B
cells that are not self-reactive leave the bone marrow as
transitional B cells. Self-reactive immature B cells will
either undergo apoptosis (clonal deletion), generate a
new B cell receptor by receptor editing, or become
unresponsive to antigen (reviewed in [26-29,31,33]).
Several transcription factors including PU.1, STAT5,
E2A (E12 and E47), EBF, Pax-5, IKZFI and FOXP1
together with cytokines (IL-7, SCF) and chemokines
(CXCL12), which are provided by the stromal cells, reg-
ulate the commitment and maintenance of B cells
(reviewed in [34,35]). Absence of IL-7 signaling leads to
developmental arrest at the pre-pro-B cell stage, show-
ing the essential role of IL-7 signaling in B cell develop-
ment in mice [36]. Downstream of IL-7, deletion of
both STAT5 and STAT3 lead to developmental arrest at
the pro-B stage [37,38]. Transcriptional regulation of B
cell development is complex and involves the interplay
of several transcription factors, including E2A, EBF,
PAX5, FOXP1 and IKZF1. E2A-null mutant mice were
unable to generate mature B cells [39], while Pax-5 is
required for commitment to the B cell lineage [40].
Deletion of EBF blocked the pro-B to pre-B transition
[41]. It has also been shown that Ebf-/- hematopoietic
cells do not express Pax-5 indicating that EBF acts
upstream of Pax-5. This finding was further supported
by the finding of an EBF-binding site in the Pax-5 pro-
moter region [42]. Foxp1 is also an essential transcrip-
tion factor for B cell development that is induced by
E2A and in turn induces expression of the Rag enzymes.
Deletion or knockdown of Foxp1 resulted in a reduction
of B cell specific gene expression and interrupted the
transition from pro-B cell to pre-B cell [35,43]. Other
transcriptional regulators of B cell development include
Ikzf1, which seems to play an important role in early
lymphoid commitment.
These repeated cycles of DNA damage and repair may
explain the reason for Pro-B and pre-B stages being
more susceptible to oncogenic transformation. Also of
interest, almost every transcriptional regulator of B cell
development is disrupted in B-lineage malignancy. E2A
has found in chromosomal translocations associated
with B-ALL, and Pax-5 deletions are common in B-ALL
[44-48]. Also in genome wide analysis, Pax-5 and EBF
have been shown to be associated with B ALL [46].
Foxp1 translocation and overexpression is noted in
mature B cell neoplasms, while IKZF1 is disrupted in
pre-B-ALL [49-60]. Hence, the study of B cell develop-
ment also informs the understanding of B cell malig-
nancy pathogenesis.
B cell development in the periphery
Mature B cells in the periphery are generally divided
into B1 and B2 cells. B2 cells are conventional B cells
that are derived from the bone marrow, undergo V(D)J
recombination, and are part of the adaptive immune
response (reviewed in [26]). A second set of recently
described B cells, called B1 cells, are characterized by a
limited immunoglobulin repertoire, and are part of the
innate immune system (reviewed in [61]). These are
best described in the mouse lymphoid system, where
they express distinct sets of markers and are located
mainly in the peritoneum and in the spleen. The lineage
origin and relationship with conventional B2 cells is not
entirely clear. The rest of our discussion will focus on
B2 cells.
The majority of the cells in the spleen and in the cir-
culation are thought to be B2 cells, and we focus the
rest of the discussion in this section of such cells. B
cells that have not encountered their specific antigen are
called naïve B cells (CD 27-, IgD+). When a B cell binds
to an antigen, it enters the germinal center of peripheral
lymphoid tissues and eventually differentiates into
plasma cells and memory cells. Plasma cells are a term-
inally differentiated, highly specialized B cell that
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secretes massive quantities of Ig, and whose differentia-
tion is mediated by activation of plasma cell transcrip-
tion factors such as Blimp1 and Xbp1 [62]. Memory B
cells are long-lived and can be re-activated during a sec-
ondary infection. The entry of the activated B cells into
primary lymphoid follicles results in the formation of
germinal centers (GCs). Follicles with germinal centers
have three distinct zones, namely dark, light and mantle
zone. Rapidly dividing B cells which are called centro-
blasts form the dark zone of the GC. CBs eventually dif-
ferentiate into non cycling centrocytes which make up
the light zone of the GC. In the GC, secondary diversifi-
cation of the immunoglobulin repertoire is achieved
through somatic hypermutation and class switch recom-
bination [63]. During this remarkable process, CBs can
refine the specificity of their antigen receptor by somatic
hypermutation of IgV gene, via the introduction of point
mutations. If this process results in enhancement of the
binding affinity for antigen, the B cell is selected for,
and it survives to differentiate further. Also during the
germinal center reaction, class switching from IgM to
any other immunoglobulin can occur. Here, the variable
portion of the heavy chain (VH exon) is brought adja-
cent to with different immunoglobulin constant regions
(CH exons). This process allows making antibodies with
different effector function. Remarkably, both of these
processes-somatic hypermutation and class-switch
recombination-are under the control of the same
enzyme, adenosine-induced deaminase (AID) [64]. CC
expressing Igs with enhanced affinity may eventually be
released as memory B cells (CD 27+) from the GC.
These memory cells are long lived and have potential to
become antibody secreting cells during secondary infec-
tion (reviewed in [29,32,65-67]).
MicroRNAs in bone marrow B cell development
As can be seen from the preceding discussion, bone
marrow B cell development is carefully orchestrated, as
only one gene locus is rearranged at a given time in a
fixed sequence. Ig rearrangement is mediated by the
sequential action of a gene regulatory network com-
posed of transcription factors and growth factor recep-
tors. miRNAs are known to act as post-transcriptional
regulators of gene expression and it therefore stands to
reason that they play a critical role in this network. The
importance of miRNAs was first established by a semi-
nal study that delineated a role for miRNAs in hemato-
poietic lineage choice selection. In this study, the
authors determined that miR-181 (now known as miR-
181a) was expressed most highly in B cells and that its
overexpression in hematopoietic stem and progenitor
cells led to increased output of B cells [68,69]. Further
studies have shown additional miRNAs of importance in
B cell development; in this section, we will focus on the
role of miR-150, miR-34a and the miR-17-92 cluster in
antigen independent B cell development at the bone
marrow.
A general role for miRNAs in B cell development has
also been established (Figure 1). The conditional knock-
out of Dicer in early B cells led to a developmental
arrest at the pro-B cell to pre-B cell transition, and also
caused an effect on antibody diversification [70]. Gene-
expression profiling from Dicer-deficient cells indicated
that Bim, a known miR-17-92 cluster target, was upre-
gulated in the mice. Functionally, B cell development
was partially rescued by concurrent Bim ablation in
Dicer-deficient mice. The implication of these studies
was that miR-17-92, via repression of Bim, was the key
player that was missing in Dicer-deficient B cell devel-
opment. The miR-17-92 cluster is located on chromo-
some 13 and encodes six different miRNAs. The cluster
is highly expressed in progenitor B cells and expression
diminishes as cells mature. Ectopic expression of the
cluster in mice resulted in expansion and activation of
all lymphocyte populations in the periphery [71]. Com-
pound heterozygous mutations of two target genes of
miR-17-92, Bim and Pten, resulted in an accumulation
of activated lymphocytes, indicating that partial repres-
sion of two targets may explain the majority of the miR-
17-92-induced phenotype [71]. Taken together these
data indicate that the miR-17-92 cluster plays a critical
role in proliferation control in B cells, in B cell develop-
ment and Ig rearrangement.
A second B cell-relevant miRNA, miR-150, is highly
expressed in progenitor B cells and levels decrease at
the pro-B cell to pre-B cell transition. miR-150 targets
the c-Myb transcription factor in B cell development
[72]. Confirming targeting, B cells that are deficient in
miR-150 showed higher levels of c-Myb, while over-
expression of miR-150 in transgenic mice caused
reduced levels of c-Myb. Over-expression of miR-150 in
mouse HSC led to a defect at the pro-B cell to pre-B
cell transition [72]. Mice with targeted deletion of miR-
150 had more B-1 cells in the spleen and peritoneal cav-
ity and fewer B-2 cells, although they appeared phenoty-
pically normal [73]. Knock-out mice for miR-150 at
baseline contained higher serum concentrations of Ig
classes, especially IgA, likely due to an expansion of B-1
cells [72]. Similarly, mice that were haploinsufficient for
c-Myb had fewer mature B cells in the spleen and fewer
B-1 cells, consistent with what was seen with the miR-
150 transgenic mice [74] These data indicate a critical
role for miR-150 during B cell development.
Along with miR-150, miR-34a is highly expressed in
progenitor cells and downregulated and the pro-B cell
to pre-B cell transition. Ig rearrangement has multiple
check points dependent on TP53 [75]. TP53 targets
miR-34a which in turn targets genes involved in cell
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cycle regulation, cell proliferation and apoptosis [76,77].
Among its targets are the anti-apoptotic protein, BCL2,
and the transcription factor Foxp1 [43,78]. Mice with
constitutive expression of miR-34a showed a block at
the pro-B cell to pre-B cell transition with a reduction
in mature B cells [43]. This arrest resulted from the
inhibition of Foxp1 which is required for early B cell
development. These findings elucidate a crucial role for
miR-34a regulation at early B cell development.
MicroRNAs in spleen and periphery B cell development
As in bone marrow B cell development, miRNAs as a
whole, as well as specific miRNAs, have now been
appreciated to play important roles in peripheral or anti-
gen-dependent B cell development (Figure 1). At the
global level, Dicer ablation in mature B cells (as opposed
to early precursor B cells) using CD21-Cre resulted in
an increase in marginal zone B cells and a decrease in
follicular B cells [23]. Mice deficient for Dicer in mature
B cells had an increased titer of autoimmune immuno-
globulins with frank autoimmune disease in a propor-
tion of the female mice. The mechanistic basis of these
findings remains to be determined, but this study sug-
gested that a miRNA may be responsible of regulating
Bruton’s tyrosine kinase. However, there are certainly
some miRNAs that play major roles in B cell develop-
ment; here we will focus on the role of miR-155, miR-
146a and miR-181a in B cell development in the spleen
and periphery.
In normal lymphopoiesis, miR-155 is expressed in
moderate level in HSCs, at high levels in the germinal
center and at much lower levels in mature B cells
[79-81]. Expression of miR-155 is rapidly induced in B
cells after engagement of the antigen receptor and expo-
sure to inflammatory mediators [82,83]. Mice lacking
miR-155 showed normal steady state immune cell popu-
lations; however, mice had a defective humoral response
when immunized [84]. This response involved impaired
germinal center formation and led to low antibody class
switching to IgG in a B cell-intrinsic manner. The tar-
gets responsible for this appear to be multiple but likely
include PU.1, SHIP1, and possibly AID [85-87]). The
inhibition of the latter target is interesting, because the
phenotype that is observed in the miR-155 deficient
mice is one of decreased class-switching, whereas dere-
pression of AID might be expected to cause increased
class switching. The targeting of AID by miR-155 was
extensively studied by mutating the binding site for
miR-155 in the AID 3’UTR and these studies deter-
mined that disruption of the interaction did indeed lead
to increased class-switching, and hence the overall effect
of miR-155 likely includes additional targets [86,87].
Overall, these data are consistent with miR-155 playing
an important role in regulating antigen-dependent B cell
development. More recently, a second miRNA has been
identified to regulate CSR- miR-181b overexpression in
B cells was found to reduce the CSR rates, possibly by
also downregulating AID [88].
The miR-146 family has distinct expression patterns
amongst various hematopoietic lineages and is involved
in maintaining lineage identity in lymphocytes. Verte-
brates have two genomic copies of the miRNA, miR-
146a and miR-146b, although the latter is likely a pseu-
dogene [89]. miR-146a is induced by Toll-like receptor
4 and latent membrane protein 1 activation, and is NF-
B dependent [83,90]. miR-146a targets IRAK1 and
TRAF6, two adapter proteins involved in Toll like recep-
tor and interleukin 1 receptor signaling [91]. The role of
miR-146a in B cells remains to be definitively deter-
mined, but overall B cell numbers are lower in miR-
146a-deficient mice as the mice have a myeloprolifera-
tive disorder. Curiously however, many mice show dra-
matic follicular hyperplasia and active germinal centers
with increased B cell function [92].
Some other miRNAs, including miR-125a, miR-125b,
miR-99b and let-7e transcripts are preferentially
expressed by the actively dividing centroblasts in germ-
inal centers. In functional assays, miRNA-125b over-
expression inhibited the differentiation of primary B
cells [93]. Hence, it can be seen that several miRNAs
show important roles during antigen-dependent B cell
development.
MicroRNAs in B cell lymphoma and leukemia
The expression of miRNAs in a particular cell type
(miRNome) can vary between normal and diseased tis-
sues. The relationship between miRNAs and cancer was
first appreciated when loss of miR-15a/16-1 was discov-
ered in chronic lymphocytic leukemia (CLL) [94]. Also,
the discovery that miRNAs were located in cancer-asso-
ciated genomic regions (CAGRs) furthered studies of
the miRNome in a vast number of cancers, from solid
tumors to hematological malignancies [95,96]. The func-
tion of miRNAs depends greatly on the cellular context
for they can act as tumor suppressor genes or onco-
genes depending on the genes that are expressed in a
given cell. In this section we will focus on miRNAs that
have been implicated in B cell lymphoma and leukemia
(Figure 2). We will focus our discussion on those miR-
NAs that have some functional role in B cell develop-
ment or lymphoma; it is beyond the scope of this review
to list the plethora of profiling studies that exist in the
literature.
Dysregulation of miR-155 and the miR-15a/16 and
miR-17-92 clusters has been implicated in B-ALL [97].
miR-155 overexpression has been observed in certain
subtypes of ALL and its over-expression in mice gives
rise to B cell lymphoproliferative disease by targeting
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the SHIP1 inositol phosphatase [98-100]. miR-16 targets
anti-apoptotic genes BCL-2, MCL1 and CDK46, thereby
acting as a putative tumor suppressor [101]. The miR-
17-92 cluster is upregulated in ALL due to copy number
amplification and direct upregulation, and transgenic
overexpression of this cluster leads to a lymphoprolifera-
tive disease in mice, as we have previously discussed (see
preceding section on miRNAs and bone marrow B cell
development [71,97]). Interestingly, overexpression of a
single miRNA, miR-21, can lead to a high-grade B-ALL
in mice and similar to protein-coding oncogenes,
demonstrates the phenomenon of “oncogene addiction”
[102].
In CLL miR-15a/16-1 dysregulation is observed along
with dysregulation of miR-34a, miR-34b, miR-34c, miR-
181b, miR-181a and miR-155. In fact miR-34a expres-
sion has recently been validated as a prognostic marker
in CLL in a fairly large clinical study [103,104]. It is
interesting to note that one of the most frequent
abnormalities in CLL is 13q14 deletion, and the search
for candidate tumor suppressor genes in the deleted
region had not been successful in the pre-miRNA era
[105]. The minimal deleted region (MDR) within 13q14
contains a long non-coding RNA (lncRNA) named
DLEU2 [106,107]. Carlo Croce and his colleagues found
that the miR-15a/16- cluster was located within intron 4
of DLEU2 [95]. This identification of the first tumor
suppressor miRNA was followed by extensive study and
delineation of multiple targets [103]. However, the for-
mal assessment of tumor suppressor function was com-
pleted much more recently. In an exacting study, Dalla-
Favera and colleagues created conditional knockout
mice with deletions of the minimal deleted region
(MDR), deleting both DLEU2 and the miRNA, or of the
miRNA cluster only [108]. Remarkably, the mice with
deletion of the miRNA only showed a pre-leukemic
expansion of B cells, while the mice with deletion of the
MDR developed a CLL-like disease. In this study, the
authors showed that there were likely multiple miRNA
targets responsible for the phenotypes observed, includ-
ing some that had been previously identified.
Dysregulation of miRNAs has also been described in
Hodgkin’s Lymphoma (HL) and Non-Hodgkin’s Lym-
phoma (NHL). In NHL miR-155, miR-21, miR-34a and
the miR-17-92 clusters have been implicated. miR-155
carries prognostic implications as high expression of the
miRNA is typical of ABC-DLBCL which has a 5 year
survival rate [109]. In vivo studies demonstrate an onco-
genic role for miR-21 in B-lymphomagenesis [102].
Mice expressing miR-21 showed a pre-B malignant lym-
phoid-like phenotype and inactivating miR-21 caused
regression of the malignancy. The miR-17-92 cluster is
upregulated in approximately 65% of lymphomas [110].
Furthermore, let-7a, miR-150 and miR-155 are found
dysregulated in HL. Let-7a is upregulated causing low
expression of PRDM1/Blimp, presumably interrupting
plasma cell differentiation [111]. Downregulation of
miR-150 and upregulation of miR-155 is common in
HL. In normal lymphopoiesis there are high levels of
miR-155 in the germinal center, where HL has its origin,
suggesting that miR-155 upregulation in HL is due to an
abnormal block of lymphocyte differentiation at the
germinal center stage [24].
Lastly, p53-mediated miRNA regulation has been
found to be important in multiple myeloma (MM), a
neoplasm of mature plasma cells. In an effort to under-
stand the miRNA effectors of p53 in this context,
Pichiorri and colleagues defined a set of p53-regulated
miRNAs, which include miR-192, miR-194, and miR-
215 that are downregulated in a subset of newly diag-
nosed MM. These miRNAs target and downregulate
MDM2, a negative regulator of p53. Hence, the expres-
sion of these miRNAs reinforces the activity of p53, and
the authors found that enforced expression of these
miRNAs had a negative effect on the growth of MM
cells. Therapeutic possibilities are suggested by the
effects of miRNA reconstitution in tempering MM cell
growth [112].
The preceding discussion should establish the contri-
bution of miRNAs in lymphoid tumorigenesis. Although
some molecular effectors of the miRNnome are known,
much remains to be discovered. miRNAs are likely to be
of use as diagnostic biomarkers for cancer and as prog-
nostic indicators. Additional work to uncover the roles
of miRNAs as therapeutic agents remains to be com-
pleted, where a major limitation remains delivery of
small RNAs into lymphoid cells.
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Figure 2 miRNA dysregulation leads to B cell malignancies.
Dysregulation of key miRNAs at different stages in B cell
development can cause malignant transformation and expansion.
ALL: B-lymphoblastic lymphoma; CLL: Chronic lymphocytic leukemia;
HL: Hodgkin lymphoma; NHL: Non-Hodgkin lymphoma; DLBCL:
Diffuse large B cell lymphoma (a type of NHL); FL: Follicular
lymphoma (a type of NHL); MM: Multiple Myeloma.
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MicroRNAs in autoimmunity
Strong responses to self-antigens are thought to be the
basis of autoimmune diseases. Many autoimmune dis-
eases are heavily dependent on T cells, but B cells are
almost certainly involved, for example, in the secretion
of autoantibodies. Indeed mice with a conditional dele-
tion of Dicer in mature B cells develop abnormal B cell
subsets, have high autoantibody titers, and female mice
develop autoimmune disease with end-organ damage.
Several specific miRNAs have been found to be dysregu-
lated in variety of autoimmune disease, and many have a
role in T-cell function [113].
It has been found that miR-146a null mice develop a
severe autoimmune disorder characterized by enlarged
spleen and lymph nodes. These null mice produced
about 60 fold higher amounts of autoantibodies against
double standard DNA than wild type mice. Autoim-
mune phenotype in miR-146a null mice is consistent
with the finding of elevated amount of activated T cells
in the periphery, but may also be dependent on
increased activation of B cells [89]. miR-146a also plays
a role in the pathogenesis of Systemic lupus erythemato-
sus (SLE). It represses the function of IFN (type one
interferon), a factor that is important in SLE, by repres-
sing the target genes such as TRAF6/IRAK1, STAT1
and TLR7 or TLR9 [114-117].
It has been found out that the generation and function
of regulatory T-cells (T reg) in autoimmunity is depen-
dent on Dicer dependent miRNA biosynthesis pathway.
Mice that have conditional deletion of Dicer in T reg
cells showed early onset of autoimmunity which is simi-
lar to the observed phenotype in Foxp3 mutant mice
that completely lack T reg cells [118,119]. Later study
showed that Foxp3 regulate the expression of miR-155
in T reg cells and deficiency of miR-155 results in
decreased number, proliferation and fitness of T reg
cells compared to wild type [120]. In a similar set of
experiments, miR-146a-deficient hematopoietic cells
failed to rescue Foxp3-deficient T-cell-mediated autoim-
munity [121].
Although the role of miRNAs in B cell-mediated auto-
immunity is less firmly established, it is likely that
further discoveries in B cells are forthcoming. Finally, it
has been shown in a pilot study that miRNA can be
potentially used as biomarkers for diagnosis and prog-
nosis of autoimmune diseases such as rheumatic dis-
eases [122].
Conclusions
The advances in understanding the biological and
pathological roles of miRNAs in B cells have been tre-
mendous in the last few years. Despite this progress,
there are many questions that remain. The first is how
extensive are the networks that are controlled by
miRNAs in B cells? Although some studies, including
our own, have shown that a single or few targets may
be critical at a given developmental stage, it remains to
be delineated whether this is generally true or if there
are multiple targets that a miRNA regulates. A second
major question, which remains largely unexplored in
mammalian systems, is how miRNA degradation is
regulated. This will help define how gene expression
programs may be regulated at one stage but not another
by a given miRNA. Lastly, the utilization of miRNA-
based therapeutics in B cell malignancies and inflamma-
tory conditions is an area of active research. There are
several avenues of promising work that suggests that we
will be able to leverage miRNA-based pathways in treat-
ing these diseases, but current challenges include deliv-
ery into specific cell-types [123]. Research into viral
vector-based delivery and into chemically modified small
RNA sequences are particularly promising, and are likely
to be the next frontiers.
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